University of Wollongong

Research Online

Faculty of Science, Medicine and Health -
Papers: part A

Faculty of Science, Medicine and Health

1-1-2017

Ebola virus disease: An update on current prevention and management strategies

Mohamad-Ali Trad

University of Wollongong, mtrad@uow.edu.au

W Naughton

Monash Health

Alison Yeung

Monash Health

L Mazlin

Medecins Sans Frontieres

M O'Sullivan

Westmead Hospital

See next page for additional authors

Follow this and additional works at: <https://ro.uow.edu.au/smhpapers>

Part of the [Medicine and Health Sciences Commons](#), and the [Social and Behavioral Sciences Commons](#)

Recommended Citation

Trad, Mohamad-Ali; Naughton, W; Yeung, Alison; Mazlin, L; O'Sullivan, M; Gilroy, N; Fisher, D A.; and Stuart, R L., "Ebola virus disease: An update on current prevention and management strategies" (2017). *Faculty of Science, Medicine and Health - Papers: part A*. 4567.
<https://ro.uow.edu.au/smhpapers/4567>

Research Online is the open access institutional repository for the University of Wollongong. For further information contact the UOW Library: research-pubs@uow.edu.au

Ebola virus disease: An update on current prevention and management strategies

Abstract

Ebola virus disease (EVD) is characterised by systemic viral replication, immuno-suppression, abnormal inflammatory responses, large volume fluid and electrolyte losses, and high mortality in under-resourced settings. There are various therapeutic strategies targeting EVD including vaccines utilizing different antigen delivery methods, antibody-based therapies and antiviral drugs. These therapies remain experimental, but received attention following their use particularly in cases treated outside West Africa during the 2014-15 outbreak, in which 20 (80%) out of 25 patients survived. Emerging data from current trials look promising and are undergoing further study, however optimised supportive care remains the key to reducing mortality from EVD.

Disciplines

Medicine and Health Sciences | Social and Behavioral Sciences

Publication Details

Trad, M. A., Naughton, W., Yeung, A., Mazlin, L., O'Sullivan, M., Gilroy, N., Fisher, D. A. & Stuart, R. L. (2017). Ebola virus disease: An update on current prevention and management strategies. *Journal of Clinical Virology*, 86 5-13.

Authors

Mohamad-Ali Trad, W Naughton, Alison Yeung, L Mazlin, M O'Sullivan, N Gilroy, D A. Fisher, and R L. Stuart

EBOLA VIRUS DISEASE: AN UPDATE ON CURRENT PREVENTION AND MANAGEMENT STRATEGIES

Abstract

Ebola virus disease (EVD) is characterised by systemic viral replication, immuno-suppression, abnormal inflammatory responses, large volume fluid and electrolyte losses, and high mortality in under-resourced settings. There are various therapeutic strategies targeting EVD including vaccines utilizing different antigen delivery methods, antibody-based therapies and antiviral drugs. These therapies remain experimental, but received attention following their use particularly in cases treated outside West Africa during the 2014-15 outbreak, in which 20 (80%) out of 25 patients survived. Emerging data from current trials look promising and are undergoing further study, however optimised supportive care remains the key to reducing mortality from EVD.

1.0 Introduction:

Based on minor variations in genomic sequences and the regions where first identified, Ebola viruses are classified into five species: *Zaire ebolavirus* (EBOV), *Sudan ebolavirus* (SUDV), *Bundibugyo ebolavirus* (BDBV), *Tai Forest ebolavirus* (TAFV), and the only Asian species *Reston ebolavirus* (RESTV).[1] The first three of these have previously caused large outbreaks in the Democratic Republic of Congo, Sudan, Gabon, Republic of Congo, and Uganda.[2] The most recent and largest outbreak involving over 28,000 cases in West Africa was caused by a variant strain of EBOV with an estimated overall case fatality rate of around 40%.[3]

EVD is primarily a diarrheal illness that requires copious amounts of fluid and electrolyte replacement.[4] Failure to address such requirements contributes

28 to mortality and thus an intensive level of support is required to optimize
29 outcomes. This is challenging in resource limited settings.

30 There were no approved therapeutics to treat Ebola virus disease (EVD)
31 during the 2014-15 outbreak, that devastated three West African countries.[5]
32 A small number of cases were treated with putative therapeutics in the U.S
33 and Europe before formalised clinical trials were established late in the
34 outbreak.[6] Potentially, an effective therapeutic available in large quantities
35 could not only treat individual cases but halt outbreaks.

36 1.1 Practicalities of clinical trials for Ebola virus disease

37 Although a number of experimental vaccines and antivirals against Ebola
38 virus had been developed prior to the large EVD outbreak in West Africa in
39 2014-15, phase II/III field studies did not get underway until late in the
40 epidemic.[6] Consequently, some studies will now have insufficient
41 recruitment to establish efficacy.[40] This highlights the unique difficulties
42 encountered in conducting clinical trials in the midst of a health emergency,
43 particularly in resource poor settings. Nevertheless, for a disease such as
44 EVD, which has such a high mortality and no proven directed therapy, it is
45 imperative that an integral part of the international response be to facilitate
46 clinical trials of therapeutic agents.

47 International agencies setting up treatment centres must be willing to recruit
48 patients into clinical trials, and have structures in place to manage the ethical
49 and medico-legal requirements to facilitate their conduct.[6] Ethical
50 considerations around the design of clinical trials in such settings can be
51 complex, and it has been argued that randomized, placebo controlled designs

are not ideal as they may lead to withholding of potentially beneficial treatment (albeit experimental) from those with a condition that otherwise has a very poor outcome.[6] Using historical controls can circumvent this issue, but calls into question the robustness of the study outcomes. Adaptive trial designs where ongoing planned interim monitoring of the outcome data can be used to alter the trial design after commencement to maximize the potential benefit to study participants while maintaining statistical reliability, have also been advocated for such studies.[55] Other challenges to conducting clinical trials in such settings are the need for study personnel to enter the “red zone” of Ebola treatment centres (ETCs) to consent patients, thereby risking exposure to Ebola themselves, obtaining consent from very unwell patients for complex studies when next of kin are unable to be present at the bedside, and co-ordinating and expediting the ethical review process between multiple governmental and non-governmental healthcare organisations and research institutions. [55] Consent procedures can be further complicated by the cultural and linguistic barriers.

This paper will review proposed therapeutics (including vaccines, antibody based therapies, and small molecules) – many of which have only been tested in vivo on rodents or non-human primates (NHPs).[2]

2.0 Vaccines against Ebola virus disease:

Vaccines are a potential cornerstone for limiting or fully preventing an EVD outbreak. There are numerous vaccine trials including two leading candidates in phase 3 trials (Table-1) rVSV-EBOV vaccines (recombinant vesicular

stomatitis virus vector) and ChAd3-ZEBOV (adenovirus vector).[7,8] Other potential candidates have been described elsewhere.[9]

2.1 Recombinant vesicular stomatitis virus vector vaccines:

When vesicular stomatitis virus was used in antigen delivery in NHPs, 50% protection was observed which was still effective up to thirty minutes post acquiring infection.[7] Recently, the interim results of a cluster randomized phase III trial of rVSV-EBOV in Guinea have been published.[10] The difficult logistics of conducting such a trial were mitigated effectively by a ring vaccination strategy, where adult contacts and contacts of contacts of patients with EVD were included. Clusters of participants were randomized 1:1 into immediate versus delayed (21 days) vaccination. Out of 2014 participants from 48 clusters in the immediate group, there were no EVD cases after 10 days post vaccination, compared to 16 cases occurring in the delayed group of 2380 participants allocated to 42 clusters. Only one case had a febrile illness associated with the vaccine, which resolved without sequelae. Although the study did not provide measures of antibody titres, it concluded that it might take up to 6 days for the vaccine to provide protection.

Prior phase 1 trials of rVSV-EBOV vaccine, including patients from various sites in the U.S, Africa and Europe, found a high number of adverse events in 90% of the study population.[11,12] The majority of events were reported as mild or moderate, appeared and subsided early (≤ 24 hours), and were alleviated with simple analgesics. Rapid onset and transient haematological changes were observed in all participants including transient leukocytopenia and lymphocytopenia. By 4 weeks, all vaccine doses produced EBOV-

glycoprotein specific antibodies, although it could not be concluded whether higher vaccine doses would be required for optimal protection.

Two further attenuated forms of rVSV: rVSVN4CT1GP1 and rVSVN1CT1GP3 were studied by Mire et al [13], following concerns of developing arthritis in some participants in prior trials [11]. None of the vaccinated experimental animals (n=8) showed any signs of severe illness when exposed to lethal challenge of EBOV.

The advantages of the rVSV vaccine platforms include a shorter time to achieve protecting antibodies by inducing humoral immunity which is key to survival in experimental subjects.[8,14] This renders them favorable in outbreak settings. The relatively low pre-existing immunity to VSV in various populations is an added value.[15] Duration of protective immunity, however, remains unknown.

2.2 Adenovirus vector vaccines:

To date there are no published phase III trials describing adenovirus vector vaccines. In a phase 1 double-blinded, placebo controlled trial of an adenovirus type-5 vector-based Ebola vaccine conducted in China [16], 120 adults received a vaccine matching the glycoprotein of the 2014 EBOV. The study demonstrated significant increase in Glycoprotein-specific antibody titres at both day 14 and day 28 ($p < 0.0001$) and the treatment was well tolerated. The generalisability of this study however is limited given the variable prevalence of baseline adenovirus type-5 neutralising antibody in different African populations.[16]

There are concerns regarding adenovirus- linked vaccination given previous failures in HIV trials, which were stopped early.[17] The vaccine may reduce suppressive regulatory cells.[18] As such, given high rates of HIV prevalence in Africa, if vaccination was to continue with an adenovirus vector vaccine, it has been suggested that HIV education and prophylaxis should be included in the vaccination regimen.[19]

In comparison to rVSV-EBOV, ChAd3-EBOV vaccines strongly induce cellular immunogenicity, which could provide longer duration of vaccine efficacy.[20] ChAd3-EBOV can potentially be boosted by a modified vaccinia Ankara (MVA) strain to produce higher and longer lasting antibody titres. [21] This advantage favours their use in pre-outbreak settings or in health care workers.

2.3 Vaccine use post exposure to Ebola Virus:

Following needle stick injury, rVSV-ZEBOV vaccine has been used in a 44 year old US physician caring for patients in an Ebola treatment unit in Sierra Leone.[22] Forty-three hours after exposure the vaccine was administered and the patient evacuated to the US. Similar to a previous case where vaccination was administered after laboratory exposure,[23] The patient had a clinical syndrome consistent with vaccination response. He developed antibodies to Ebola virus glycoprotein (a vaccine component), but not to Ebola virus VP40, which would be indicative of natural infection.

2.4 Other Antigen and vaccine delivery methods:

Cytomegalovirus (CMV) based vaccination has also been studied in rodents.[24] A single dose of CMV expressing a CD8 T cell epitope from nucleoprotein of Ebola Virus (designated MCMV/ZEBOV-NPCTL) induced

147 durable CD8+T cell immunity for at least 33 weeks. No EBOV disease was
148 observed in vaccinated mice when challenged. These mice did however show
149 loss of weight, suggesting protection may be only partial.

150 The intranasal route has also been suggested as a potentially effective
151 vaccine delivery method.[25] This method has the potential to increase
152 acceptance, especially in populations distrustful of Western medicine.
153 Intranasal vaccines target the mucosal sites at which Ebola is contracted,
154 minimise the need for specialised health care workers in resource deplete
155 settings and reduce cost. They also decrease storage requirements, minimise
156 medical waste and reduce the need for populations to travel to be vaccinated.

157 **3.0 Antibody based therapies:**

158 Human survivors of EBOV tend to mount early, vigorous, and long standing
159 neutralizing antibodies (NAbs) that can bind to EBOV structural envelop
160 glycoprotein (GP).[52] Identification of such NAbs and their mechanism of
161 activity has been essential in the development of immunotherapies and
162 vaccines against EBOV. The breadth of protection of such NAbs is variable
163 and still undergoing study.[53]

165 **3.1 Convalescent Blood Products**

166 Convalescent blood products have been used during Ebola outbreaks under
167 the pretext that they contain NAbs against EBOV.[26] In one of the earliest
168 landmark studies, from the Kikwit outbreak in 1995, whole blood transfusions
169 were donated by five convalescent patients, to eight patients with EVD. Five
170 of the six patients tested demonstrated negative tests for EBOV antigens by

day 4 after receiving their transfusions. The mortality rate for this patient group was 12.5% (1 in 8), which was smaller than the 80% overall mortality for the outbreak. Whether these results can be generalized is unknown, as the study was limited by its small number of patients and lack of controls. Additionally, the intervention was undertaken during the late phase of the epidemic when health resources were greatly improved. There have also been suggestions that at the end of an EBOV epidemic, the virus may become less infectious and less virulent.[27] A more recent, larger, and better designed study that included 99 patients from Guinea did not show a statistically significant survival benefit in receiving up to 500 ml of convalescent plasma.[28] Paediatric patients younger than 5 years of age appeared to benefit from the transfusions, however a conclusion could not be made due to the low numbers. The study was conducted towards the end of the outbreak, when mortality rates were less than 20%. Due to logistics, the convalescent plasma NAb levels were not tested, but this reflected real life settings. It has been suggested that convalescent blood products after 9 months from recovery might contain higher levels of NAb and hence be more protective.[29] At least 8 patients treated outside Africa have reportedly received convalescent serum, 7 of whom survived. [3,41-5]

3.2 Monoclonal antibody combinations (ZMapp, MB-003, and ZMab)

A single antibody may not be able to neutralize every single viral particle, and hence a cocktail of antibodies may be required. Neutralising antibodies from convalescent blood can be produced in vitro in the form of cocktails of monoclonal antibodies (mAbs) against EBOV glycoprotein (GP). For example, ZMapp is a cocktail of 3 chimeric mAbs (c13C6, c2G4 and c4G7), ZMab a

196 cocktail of mouse mAbs (m1H3, m2G4, m4G7), and MB003 a cocktail of
197 human-mouse chimeric mAbs (c13C6, h13F6, c6D8) (Table-1). Four out of six
198 patients treated outside Africa have reportedly received ZMapp and survived.
199 [3,41-5] Details of those therapies, including timing and doses of serum or
200 antibody cocktails remain unpublished. Compared to vaccines that require
201 longer time to induce protection, antibody-based-therapies can potentially
202 offer protection immediately after EBOV exposure for up to 120 hours in
203 animal models [30] (Table-1). Their major drawbacks however are a lack of
204 availability and a significantly declining efficacy when given later in the course
205 of experimental infection.

206 Qiu et al. investigated the administration of ZMAb.[31] All four NHPs (100%)
207 receiving the cocktail at 24 hours post EBOV challenge survived whilst two
208 (50%) survived in the 48-hour group. Of note one of the non-survivors carried
209 an escape mutant with mutations in EBOV-GP (amino acids 275 and 508).
210 EBOV-GP IgM and IgG were present up till day 28. ZMAb half-life is still
211 unknown and as such timing of treatment and dosing still require further
212 investigation. Two patients with EVD in the latest outbreak in Sierra Leone,
213 who were treated in Europe, received ZMAb and survived. [45, 56]

214 In a previous study utilizing NHPs, co-administration of mAb and adenovirus-
215 vectored interferon- α (Ad-IFN) demonstrated effectiveness if provided
216 following the third day of infection.[32] Seven of eight NHPs survived
217 challenge with signs of mild disease. In a further design to test for an
218 extension of the potential treatment window, NHPs were treated with Ad-IFN
219 24 hours after challenge and ZMAb at 96 hours after challenge. Two of four
220 NHPs survived infection. [32]

The delayed administration of MB-003, manufactured in the tobacco plant *Nicotiana benthamiana*, was investigated for efficacy in NHPs.[30] Treatment was initiated at 120 hours after infection with EBOV, with further administration of MB-003 at 170 and 250 hours post exposure. Only 3 of 7 NHPs survived, and all controls died.

3.3 Other antibody based therapies

The phosphatidylserine-targeting antibody (PGN401, bavituximab), an antibody previously demonstrated to have broad-spectrum antiviral activity, was shown in an in vitro trial to bind and recognise Ebola virus and Ebola virus infected cells.[33] This may also be a future treatment modality.

The above studies may be limited in their generalisability to human subjects. The cohort numbers were low, which would also limit the power to detect rare adverse outcomes of treatment administration.

4.0 Drugs and small molecules:

4.1 Favipiravir:

The pyrazinecarboxamide derivative T-705 (favipiravir) is licensed in Japan for the treatment of influenza not responding to conventional therapies.[34] It has antiviral activity against other negative stranded RNA viruses, and has been used in the European centres that treated EVD in the last outbreak (Table-1). It induced rapid Ebola viral clearance in a rodent model when administered as late as day 6 following inoculation with Ebola virus, in addition to a 100% survival rate compared to controls (100% fatality rate).

Results from the JIKI trial in Guinea led by the French Institute of Health and Medical Research (INSERM) suggest a non-significant lower mortality in those with low viral loads as indicated by an EBOV RT-PCR cycle to threshold (CT) of > 20 (20% vs 30% in historic controls) but not in those with high viral loads (CT <20), with a 91% mortality rate in those treated with favipiravir vs 85% in historic controls.[35] The anti-EVD regimen used in adults was 6,000 mg on day 0, followed by 2,400 mg/d from day 1 to day 9, whereas doses in children were adjusted to body weight [36].

4.2 Phosphorodiamidate morpholino oligomers and small interfering RNAs:

Molecules such as phosphorodiamidate morpholino oligomers (PMOs), and small interfering RNAs (siRNAs) have shown efficacy in reducing mortality when administered to NHPs up to 1 hour after exposure.[37,38] AVI 6002 is a combination of positively charged phosphorodiamidate morpholino oligomers (PMOs) designed to target mRNA sequences of VP24 and VP35 in EBOV. It is currently undergoing phase I clinical trials for EBOV post exposure treatment. In a study in 2010, AVI-6002 was given intravenously to NHP's initiated 30-60min post EBOV exposure at varying doses for up to 14 days.[38] The results of the study demonstrated that 60% of NHPs given doses of 28mg/kg and 40mg/kg survived with 100 times greater suppression of mean viral load at the peak of plasma viraemia compared to controls. Phase I safety trials have shown AVI 6002 to be well tolerated in healthy adult subjects. TKM-Ebola (formerly Tekmira), is a combination of small interfering RNAs (siRNAs) formulated in stable nucleic acid lipid particles was developed by Tekmira Pharmaceutical Corp. The combination of siRNAs targeting the EBOV L polymerase, VP 24 & 35, was given to 7 NHPs at 30 minutes post

exposure to EBOV and either 3 or 6 further doses at various intervals after.[37] Six of the 7 NHPs were protected from EBOV infection with good tolerance of the drug. During its phase I clinical trial, the U.S Food and Drug Administration placed a hold on the drug due to safety concerns in regards to high cytokine levels.[57] This was partially lifted during the outbreak, and subsequently used in two patients who were treated in the U.S.[58] Furthermore, it is also being designed to target the Guinea variant of EBOV and was planned to enter human clinical evaluation in Guinea in emergency situations.[57]

4.3 Brincidofovir CMX001

CMX001 (Brincidofovir) is a prodrug of cidofovir and is an effective anti-DNA antiviral medication by inhibiting viral replication secondary to selectively inhibiting viral DNA polymerases.[39] It is currently undergoing Phase III clinical trials for use against adenovirus and cytomegalovirus. In vitro tests have demonstrated efficacy against EBOV although the mechanism of action is unclear.[39] As a result, Brincidofovir has been used in emergency situations in patients infected with EBOV and was undergoing Phase II clinical trials, which were unfortunately halted due to lack of new cases. Brincidofovir was experimentally used to treat one of the first patients to be transferred to the U.S.[41]

4.4 BCX443:

The adenosine analogue, BCX443, when given 48 hours after infection via intramuscular injection demonstrated 100% protection from Marburg virus in a

nonhuman primate model (Table-1), and could potentially be used for EVD.[40] BCX4430 inhibits viral RNA polymerase activity indirectly through non-obligate RNA chain termination. It has shown efficacy in pre-exposure treatment of EBOV in vitro and in small animal models. In a rodent model, it demonstrated protection against lethal EBOV challenge receiving BD oral and IM administration for nine days.[40] BCX4430 is planned for further animal studies.

5.0 Supportive care

In the absence of any available directed therapy, the mainstay of management in EVD has been supportive care. This includes rehydration, electrolyte replacement, supplemental oxygen, treatment of concomitant infections, blood products, antipyretics, anti-emetics and anti-diarrhoeal agents, nutritional support and psychologic care. The level of sophistication of these interventions varies from basic oral rehydration therapy without laboratory investigations in the most resource poor settings, through to invasive fluid, electrolyte and blood product management, mechanical ventilation, and haemodialysis with full laboratory and radiology support in intensive care units in developed countries.[42] Even within countries most affected by EVD, the level of supportive care varied widely.[59,60] Whether increasing sophistication of supportive care is associated with improved outcomes is not proven, however, one could not dispute this intuitively. In an observational study, Cotte et al compared the use of central venous catheters to peripheral venous catheters for IV access in patients treated at an Ebola Treatment Unit in Conakry in 2015. Central catheters were associated with

longer line survival times and a higher ratio of volume of fluid infused to that which was prescribed.[61]

5.1 Authors' remarks

Case management varied widely due to a variety of reasons. In one major centre in Liberia, during the peak of the outbreak, the case numbers overwhelmed the ETC capacity that a decision was made to “close the doors”, and a palliative approach was followed due to high rates of mortality (reaching 80%).[Box-1] In a different setting, the case load was lower. Patients with confirmed EVD were admitted to air conditioned tents, each containing two beds. Observations included temperature, blood pressure, pulse, oxygen saturations, respiratory rate, conscious state (AVPU) and level of hydration. Frequency of observation was between 12th hourly up to 4th hourly or more frequently, depending on the stage of disease. Fluid balance was recorded, and urinary catheterisation and rectal tubes (Flexiseal Faecal Management System) were utilised as needed. Closed circuit cameras allowed continuous remote visual observation of patients from the staff station outside the ‘red zone’. Peripheral venous access was established when necessary for intravenous hydration; central venous access was also utilised for patients with advanced disease. Ultrasonography was utilised to aid placement of central venous catheters, and also to assess fluid volume status by observing inferior vena cava filling.

Point of care pathology testing was utilised within the red zone, using iSTAT™ devices (analytes tested included sodium, potassium, chloride, ionised calcium, glucose, urea, bicarbonate, creatinine, haematocrit, haemoglobin,

anion gap, pH, PCO₂, pO₂, lactate, base excess, prothrombin time, INR),
glucometers, and immunochromographic testing for malaria and beta-HCG.

An onsite laboratory performed PCR testing for Ebola virus, as well as rapid
diagnostic tests for Dengue and HIV. In the laboratory, biochemistry testing
was available using the Piccolo™ platform. Analytes assayed on the
Piccolo™ included albumin, urea, calcium, creatinine, glucose, potassium,
sodium, amylase, alanine transaminase, aspartate transaminase, creatinine
kinase, C-reactive protein, bilirubin, lactate, chloride, magnesium, phosphate
and bicarbonate). Haematology testing was performed on the Hemochron™
platform and included a full blood count with white cell differential and
coagulation testing. Blood cultures were performed using the BacT/Alert™
system. The Biofire filmarray™ platform was also utilised for multiplex PCR
testing of respiratory and faecal pathogens, and to detect bacteria from
positive blood cultures.

Pathology testing was performed at least daily in the initial phase of
management, and as required in the convalescent phase. In advanced
disease point of care testing in the red zone was utilised as clinically
necessary for more frequent pathology monitoring.

Box 1- Tips in resource limited settings

- Early administration of anti-emetics and anti-diarrhoeal agents
- Test and treat concurrent infections such as malaria
- Healthcare worker training and education in principles and practice of infection control, sharps management, and occupational safety in an

ETC setting

- Dedicated staff health clinics given higher mortality rates among healthcare workers. [62]
- Early involvement of patients and their carers with ongoing education and psychologic care
- Establish a survivor network for potential training and recruitment
- Use of technology and minimisation of paper work: example, mobile phones and dedicated computers
- Early coordination between all actors

5.2 Mental health

In our experience, psychosocial support and health promotion (PSHP) are integral to the care of patients with EVD. In West Africa, many ETCs were supported by dedicated PSHP teams, responsible for counselling relatives of those admitted with EVD, coordinating “fence line” visits, linking up family members admitted to different ETCs, coordinating safe and dignified burials and allowing family members the possibility of viewing the face of the deceased, across the fence line separating red zone from the ETC boundary. PSHP personnel were critical in facilitating access to social support programs for survivors (food packages, survivor clinics, survivor networks) and providing education and counselling, including safe sexual practices, in EVD survivors. They provided an essential point of contact for many survivors who experienced discrimination in the aftermath of their disease.

Mental health of healthcare workers (HCWs) must also not be neglected. Many returning volunteers experienced stigmatisation. The names of those HCWs who contracted the illness were publicised.[63] Employers could play a role in mitigating the sensationalism driven by media by counseling families prior to an individual's return.

6.0 Follow-up

With around 10,000 survivors of this disease now across West Africa, there is an increasing demand for the medical management of complications related to EVD in this survivor cohort. Most notably ocular complications, chronic pain – especially arthralgias, cognitive, post traumatic stress syndrome and hearing deficits.[64] The emerging knowledge regarding immune privileged sites (e.g, eye, semen, cerebrospinal fluid) where the virus can remain sequestered, highlights the importance of ongoing follow-up and monitoring of these patients for late effects.[65] Such clinics are now being established in countries that have experienced high and intense transmission.

7.0 Discussion:

To date there are numerous therapeutic options that have been trialled against EVD, however, data remain scarce to fully recommend any particular therapy. Management of EBOV infection must emphasize a holistic approach that includes symptomatic control and takes into consideration the psychosocial complexities of having the disease and domestic conditions.

403

404 There is evidence that current vaccines might have the potential to halt an
405 outbreak, if a ring vaccination strategy is followed.[10] Both candidate
406 vaccines seem to be well tolerated, however, we still do not have data on the
407 duration of their protection or safety in subjects with underlying disease or
408 medical conditions. There are also no data regarding their safety in paediatric
409 or pregnant populations.

410

411 Supportive strategies and blood products have been commonly used, and
412 there is accumulating evidence towards their benefit.[61] Intravenous (IV) fluid
413 and electrolyte replacement are potentially challenging in certain contexts due
414 to the lack of infrastructure for sharps management. Their use could be
415 gradually introduced depending on the capacity of the ETC. EVD patients can
416 experience difficulties with absconding, denial and combativeness and it is not
417 uncommon for patients to remove their lines, especially when not observed.

418

419 Other clinical supportive measures can include the use of antipyretics and
420 anxiolytics for symptom control when needed. Identifying and treating
421 concurrent infections such as malaria was shown to reduce mortality.[54]

422

423 The orally administered therapeutics seem promising, especially if given early
424 when the viral load is still low. [35] Concomitant administration of anti-emetics
425 might be essential. Given the nature of increased volume losses in EVD,
426 absorption of oral medications might become an issue. To date there are no
427 intravenous formulations for those orally administered drugs.

428

429 **8.0 Conclusion:**

430 A number of treatment strategies for EBOV infection, available for some years
431 remain in the research pipeline. It took this calamitous outbreak to mobilise
432 resources to move some of them along, but it was too late. The challenging
433 local conditions and absence of working health infrastructures further
434 compounded the initiation of clinical trials. Conducting investigations in
435 outbreak settings will remain a source of debate and ethical dilemmas,
436 especially in suspicious communities and when engaging care givers
437 (individuals and government and non-government organisations) unfamiliar
438 with the conduct of trials, randomization, placebos and the like. The success
439 of any trial or public health intervention should engage the expertise of cultural
440 anthropologists. Multidisciplinary collaboration, and delivering health services
441 at a community level in the future will establish trust, capacity building, and
442 improve response.

443 Clinics to follow-up on the survivors to establish the natural history of EVD
444 and its long term sequelae is an apparently straight forward opportunity for us
445 to learn.

446 It is to the credit of WHO to establish a research and development blueprint
447 for action to prevent epidemics by accelerating availability of vaccines,
448 effective tests, and medicines at a large scale. [66] Indeed, there is a pipeline
449 of interesting molecules that potentially could target EBOV.[69] We hope this
450 will be a significant effort towards an evolving leadership in emergency
451 research, and in particular facilitating clinical trials in outbreaks. An external

investigation following the outbreak has created an opportunity for WHO “to re-establish its pre-eminence as the guardian of global public health”.[67]

It remains unfortunate that an outbreak involving 28,000 people over more than a year has passed and the opportunity to evaluate so many putative therapeutics has been missed. While some therapeutics were used on human subjects for the first time, we still cannot make conclusions on their safety or effectiveness. Clinicians and outbreak responders look forward to the day that well designed and practical clinical trials can be seamlessly rolled out in parallel with clinical efforts.

References

1. Bukreyev AA, Chandran K, Dolnik O, Dye JM, Ebihara H, Leroy EM et al. Discussions and decisions of the 2012-2014 International Committee on the Taxonomy of Viruses (ICTV) Filoviridae Study Group, January 2012-June 2013. Arch Virol 2014;159(4):821-830 doi: 10.1007/s00705-013-1846-9
2. Feldmann H, and Geisbert TW. Ebola haemorrhagic fever. Lancet 2011;377:849-62.
3. Baize S, Pannetier D, Oestereich L, Reiger T, Koivogui L, Magassouba N. et al. Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med 2014;371:1418- 25
4. Lyon GM, Mehta AK, Varkey JB, Brantly K, Plyler L, McElroy AK, et al. Clinical Care of Two Patients with Ebola Virus Disease in the United States. November 12, 2014 (epub ahead of print) DOI: 10.1056/NEJMoa1409838
5. <http://www.cdc.gov/vhf/ebola/treatment/> Last accessed on 5/10/2016
6. Mohammadi D. First trials for Ebola treatments announced. The Lancet 2014;

477 384 (9957): p1833. DOI: 10.1016/S0140-6736(14)62043-2

478 7. Feldmann H, Jones SM, Daddario-DiCaprio KM, Geisbert JB, Ströher U,
 479 Grolla A, Bray M, et al. Effective post-exposure treatment of Ebola infection.
 480 PLoS Pathog. 2007 Jan;3(1):e2.

481 8. Choi WY, Hong KJ, Hong JE, and Lee WJ. Progress of vaccine and drug
 482 development for Ebola preparedness. Clin Exp Vaccine Res 2015;4:11-16
 483 doi:10.7774/cevr.2015.4.1.11

484 9. Marzi A and Feldmann H. Ebola virus vaccines: and overview of current
 485 approaches. Expert Rev Vaccines 2014;13(4): 521-531. Doi:
 486 10.1586/14760584.2014.885841

487 10. Henao-Restrepo AM, Longini IM, Egger M, Dean N, Edmunds WJ, Camacho
 488 A et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing
 489 Ebola surface glycoprotein: interim results from the Guinea ring vaccination
 490 cluster-randomised trial. Lancet 2015; 386:857-66

491 11. Agnandji ST, Huttner A, Zinser ME, Njuguna P, Dahike C, Fernandes JF et al.
 492 Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. NEJM.
 493 2016;374:1647-60. Doi:1056/NEJMoA1502924. Epub 2015 Apr 1

494 12. Regules JA, Beigel JH, Paolino KM, Voell J, Castellano AR, Munoz P, et al. A
 495 Recombinant Vesicular Stomatitis Virus Ebola Vaccine — Preliminary Report
 496 NEJM. April 1, 2015

497 13. Mire C, Matassov D, Geisbert J, Latham TE, Agans KN, Xu R, et al. Single-
 498 dose attenuated Vesiculovax vaccines protect primates against Ebola
 499 Makona virus. Nature, 2015. doi:10.1038/nature14428

500 14. Wong G, Richardson JS, Pillet S, Patel A, Qiu X, Alimonti J, et al. Immune
 501 parameters correlate with protection against ebola virus infection in rodents
 502 and nonhuman primates, Sci Transl Med. 2012;4(158): 158ra146. Doi:
 503 10.1126/scitranslmed.3004582

15. Mast TC, Klerstead L, Gupta SB, Nikas AA, Kallas EG, Novitsky V, et al. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralising antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. *Vaccine* 2010;28(4):950-7. Doi: 10.1016/j.vaccine.2009.10.145
16. Zhu FC, Hou LH, Li JX, Wu SP, Liu P, Zhang GR, et al. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. *Lancet*. 2015;385:2272-9. doi:10.1016/S0140-6736(15)60553-0. Epub 2015 Mar 25
17. Steinbrook R. One step forward, two steps back—will there ever be an AIDS vaccine? *N Engl J Med* 2007;357:2653-5.
18. Flamming A. HIV vaccine failure due to induction of immune suppressors? *Nature Reviews Drug Discovery* 2014(13): p574-5 doi:10.1038/nrd4398
19. Kremer EJ, and Van de Perre P. Ebola vaccines based on adenovirus vectors and risk of HIV. *BMJ* 2015;350:h1307
20. Lu S, Wang S, Grimmes-Serrano JM. Current progress of DNA vaccine studies in humans. *Expert Rev Vaccines* 2008;7:175-91
21. Ewer K, Rampling T, Venkatraman N, Bowyer G, Wright D, Lambe T et al. A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA. *N Engl J Med* 2016 374(17):1635-46 doi: 10.1056/NEJMoa1411627
22. Lai L, Davey R, Beck, A. Emergency Postexposure Vaccination With Vesicular Stomatitis Virus–Vectored Ebola Vaccine After Needlestick. *JAMA*. 2015;313(12):1249-1255. doi:10.1001/jama.2015.1995
23. Günther S, Feldmann H, Geisbert TW, Hensley LE, Rollin PE, Nichol ST, et al. Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. *J Infect Dis*. 2011;204(suppl 3):S785-S790.

24. Tsuda Y, Parkins CJ, Caposio P, Feldmann F, Botto S, Ball S, et al. A cytomegalovirus-based vaccine provides long-lasting protection against lethal Ebola virus challenge after a single dose. *Vaccine*. 2015;33:2261-6. doi:10.1016/j.vaccine.2015.03.029
25. Jonsson-Scmunk K, and Croyle M. A long-lasting, single-dose nasal vaccine for Ebola: a practical armament for an outbreak with significant global impact. *Expert Rev. Anti Infect. Ther*. 2015;13(5), 527–530
26. Mupapa K, Massamba M, Kibadi K, Kuvula K, Bwaka A, Kipasa M, et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. *J Infect Dis*. 1999;179 Suppl 1:S18-23.
27. Baron RC, Mc Cormick JB, Tubeir OA. Ebola virus disease in Southern Sudan: hospital dissemination and intrafamilial spread. *Bull World Health Organ* 1983;61:997–1003
28. Van Grienswen J, Edwards T, de Lamballerie X, Semple MG, Gallian P, Baize S, et al. Evaluation of convalescent plasma for Ebola virus disease in Guinea. *N Engl J Med* 2016; 374:33-42 doi: 10.1056/NEJMoa1511812
29. Luczkowiak J, Arribas JR, Gomez S, Jimenez-Yuste V, de la Calle F, Viejo A, et al. Specific neutralizing response in plasma from convalescent patients of Ebola virus disease against the West Africa Makona variant of Ebola virus. *Virus Res*. 2016; 213:224-9 doi: 10.1016/j.virusres.2015.12.019
30. Pettitt J, Zeitlin L, Kim do H, Working C, Johnson JC, Bohorov O, et al. Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. *Sci Transl Med*. 2013;5:199ra113. doi: 10.1126/scitranslmed.3006608
31. Qiu. X. Audet. J. Wong. G, Pillet S, Bello A, Cabral T, et al. Successful Treatment of Ebola Virus–Infected Cynomolgus Macaques with Monoclonal

558 Antibodies. *Sci Transl Med.* 2012;4:138ra81.
559 doi:10.1126/scitranslmed.3003876

560 32. Qiu. X. Wong. G. Fernando. L, Audet J, Bello A, Strong J, et al. mAbs and
561 Ad-Vectored IFN- α Therapy Rescue Ebola-Infected Nonhuman Primates
562 When Administered after the Detection of Viremia and Symptoms. *Sci Transl*
563 *Med.*2013;5:207ra143 doi:10.126/scitranslmed.3006605

564 33. Dowall SD, Graham VA, Corbin-Lickfett K, Empig C, Schlunegger K, Bruce
565 CB, et al. Effective Binding of a Phosphatidylserine-Targeting Antibody to
566 Ebola Virus Infected Cells and Purified Virions. *Journal of Immunology*
567 *Research* Vol. 2015, Article ID 347903, 9 pages, 2015.
568 Doi:10.1155/2015/347903.

569 34. Oestereich L, Lüdtke A, Wurr S, Rieger T, Muñoz-Fontela C, Günther S.
570 Successful treatment of advanced Ebola virus infection with T-705 (favipiravir)
571 in a small animal model. *Antiviral Res.* 2014 ;105:17-21

572 35. Sissoko D, Laouenan C, Folkesson E, M'Lebing A-B, Beavogui A-H, Baize S,
573 et al. (2016) Experimental Treatment with Favipiravir for Ebola Virus Disease
574 (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in
575 Guinea. *PLoS Med* 13(3): e1001967. doi:10.1371/journal.pmed.1001967

576 36. Bouazza N, Treluyer J-M, Foissac F, Mentré F, Taburet A-M, Guedj J, et al.
577 Favipiravir for children with Ebola. *Lancet.* 2015;385:603–604. doi:
578 10.1016/s0140-6736(15)60232-x

579 37. Geisbert TW, Lee AC, Robbins M, Geisbert JB, Honko AN, Sood V, et al.
580 Postexposure protection of non-human primates against a lethal Ebola virus
581 challenge with RNA interference: A proof-of-concept study. *Lancet* 2010; 375:
582 1896–1905

583 38. Warren TK, Warfield KL, Wells J, Swenson DL, Donner KS, Van Tongeren
584 SA, et al. Advanced antisense therapies for postexposure protection against

585 lethal filovirus infections. Nat Med. 2010 Sep;16(9):991-4. doi:
586 10.1038/nm.2202.

587 39. Florescu DF, Keck MA. Development of CMX001 (Brincidofovir) for the
588 treatment of serious diseases or conditions caused by dsDNA viruses. Expert
589 Rev Anti Infect Ther. 2014 Oct;12(10):1171-8.
590 doi: 10.1586/14787210.2014.948847

591 40. Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL, Van Togeran SA,
592 et al. Protection against filovirus diseases by a novel broad-spectrum
593 nucleoside analogue BCX4430. Nature 2014; 508:402–405

594 41. Florescu DF, Kalil AC, Hewlett AL, Schuh AJ, Stroher U, Uyeki TM et al.
595 Administration of Brincidofovir and convalescent plasma in a patient with
596 Ebola virus disease. Clin Infect Dis 2015; 61(6):969-73 doi:
597 10.1093/cid/civ395

598 42. Wolf T, Kann G, Becker S, Stephan C, Brodt HR, de Leuw P et al. Severe
599 Ebola virus disease with vascular leakage and multiorgan failure: treatment of
600 a patient in intensive care. 2014 Dec 19. pii: S0140-6736(14)62384-9. doi:
601 10.1016/S0140-6736(14)62384-9

602 43. Kreuels B, Wichmann D, Emmerich P, Schmidt-Chanasit J, de Heer G, Kluge
603 S, et al. A case of severe Ebola virus infection complicated by gram-negative
604 septicemia. NEJM 2014;371(25):2394-401. doi: 10.1056/NEJMoa1411677

605 44. Parra J, Salmeron O, and Velasco M. The First Case of Ebola Virus Disease
606 Acquired outside Africa. NEJM 2014; 371:2439-2440

607 45. Lópaz MA, Amela C, Ordobas M, Domínguez-Berjón MF, Álvarez C, Martínez
608 M, et al. First secondary case of Ebola outside Africa: epidemiological
609 characteristics and contact monitoring, Spain, September to November 2014.
610 Euro Surveill. 2015;20(1):pii=21003

46. Sullivan NJ, Geisbert TW, Geisbert JB, Xu L, Yang Z, Roederer M, et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. *Nature* 2003; 424: 681- 4
47. Stanley DA, Honko AN, Asiedu C, Trefry JC, Lau-Kilby AW, Johnson JC, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. *Nat Med.* 2014 Oct;20(10):1126-9. Doi:10.1038/nm.3702
48. Thomas N; Novavax. Study to evaluate the immunogenicity and safety of an Ebola virus glycoprotein vaccine in healthy subjects. In: ClinicalTrials.gov [internet] Bethesda (MD): National Library of Medicine (US). 2000- [cited 2016 Jun 8]. Available from: <http://clinicaltrials.gov/show/NCT02370589>. NLM Study identifier: NCT02370589.
49. Dye JM , Herbert AS, Kuehne AI, Barth JF, Muhammad MA, Zak SE, et al. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. *PNAS* 2012; 109 (13): 5034-39 doi:10.1073/pnas.1200409109
50. Olinger GG Jr1, Pettitt J, Kim D, Working C, Bohorov O, Bratcher B, et al. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. *Proc Natl Acad Sci U S A.* 2012 Oct 30;109(44):18030-5. doi: 10.1073/pnas.1213709109
51. Liberia-U.S. Clinical Research Partnership Opens Trial to Test Ebola Treatments
<http://www.niaid.nih.gov/news/newsreleases/2015/Pages/ZMapp.aspx>
accessed 27/2/15
52. Shedlock DJ, Bailey MA, Popernack PM, Cunningham JM, Burton DR, and Sullivan NJ. Antibody mediated neutralization of ebola virus can occur by 2 distinct mechanisms. *Virology* 2010;401(2):228-235
doi:10.1016/j.virol.2010.02.029

53. <http://hfv.lanl.gov/content/sequence/HFV/ToolsOutline.html> Accessed
4/3/2016
54. Gignoux E, Azman AS, de Smet M, Azuma P, Massaquoi M, Job D et al.
Effects of Artesunate-Amodiaquine on mortality related to Ebola virus
disease. *N Engl J Med*. 2016; 374(1): 23-32. Doi:10.1056/NEJMoa1504605
55. Cooper BS, Boni MF, Pan-ngum W, Day NPJ, Horby PW, Olliaro P, et al.
Evaluating Clinical Trial Designs for Investigational Treatments of Ebola Virus
Disease. *PLoS Med*. 2015; 12(4): e1001815.
doi:10.1371/journal.pmed.1001815
56. Petrosillo N, Nicastrì E, Lanini S, Capobianchi MR, Di Caro A, Antonini M, et
al. Ebola virus disease complicated with viral interstitial pneumonia: a case
report. *BMC Infect Dis*. 2015;15:432. doi:10.1186/s12879-015-1169
57. Shurtleff AC, Whitehouse CA, Ward MD, Cazares LH, and Bavari S. Pre-
symptomatic diagnosis and treatment of filovirus diseases. *Front Microbiol*.
2015;6:108. Published online 2015 February 20.
Doi:10.3389/fmicb.2015.00108
58. Kraft CS, Hewlett AL, Koepsell S, Winkler AM, Kratchvill CJ, Larson L et al.
The use of TKM-100802 and convalescent plasma in 2 patients with Ebola
virus disease in the United States. *Clin Infect Dis*. 2015; 61(4): 496-502. Doi:
10.1093/cid/civ334
59. Wong K, Perdue C, Malia J, Kenney JL, Peng S, Gwathney JK et al.
Supportive Care of the First 2 Ebola Virus Disease Patients at the Monrovia
Medical Unit *Clin Infect Dis*. (2015) 61 (7): e47-e51 first published online May
28, 2015 doi:10.1093/cid/civ420
60. O'Shea MK, Clay KA, Craig DG, Moore AJ, Lewis S, Espina M et al. Case
Report: A Health Care Worker with Ebola Virus Disease and Adverse
Prognostic Factors Treated in Sierra Leone *Am J Trop Med Hyg* 15-0461;
Published online February 22, 2016, doi:10.4269/ajtmh.15-0461

61. Cotte J, Cordier PY, Bordes J, Janvier F, Esnault P, Kaiser E et al. Fluid resuscitation in Ebola Virus Disease: A comparison of peripheral and central venous accesses. *Anaesth Crit Care Pain Med*. 2015 Dec;34(6):317-20. doi: 10.1016/j.accpm.2015.06.010. Epub 2015 Nov 2)
62. Evans DK, Goldstein M, and Popova A. Health-care worker mortality and the legacy of the Ebola epidemic. *Lancet Glob Health*. 2015; 3(8):e439-40 doi: 10.1016/S2214-109X(15)00065-0
63. <http://www.nbcdfw.com/news/health/Ebola-Patient-Dr-Kent-Brantly-to-Leave-Hospital-Thursday-272102161.html> Last accessed 6/7/16
64. Tiffany A, Vetter P, Mattia J, Dayer JA, Bartsch M, Kasztura M et al. Ebola Virus Disease Complications as Experienced by Survivors in Sierra Leone *Clin Infect Dis*. first published online March 21, 2016 doi:10.1093/cid/ciw158
65. Sow MS, Etard JF, Baize S, Magassouba N, Faye O, Msellati P, et al. New evidence of long-lasting persistence of Ebola virus genetic material in semen of survivors. *J Infect Dis*. 2016 May 3. Pii:jiw078. [Epub ahead of print]
66. www.who.int/csr/research-and-development/blueprint/en Last accessed on 3/10/2016
67. www.who.int/csr/resources/publications/ebola/report-by-panel.pdf?ua=1 Last accessed 3/10/2016
68. Davidson E, Bryan C, Fong RH, Barnes T, Pfaff JM, Rucker JB, et al. Mechanism of binding to Ebola virus glycoprotein by the ZMapp, ZMAb, and MB-003 cocktail antibodies. *J Virol*. 2015; 89(21):10982-92 doi: 10.1128/JVI.01490-15
69. Baranovskiy AG, Babayeva ND, Suwa Y, Gu J, Pavlov YI, Tahirov TH. Structural basis for inhibition of DNA replication by aphidicolin. *Nucleic Acids Res*. 2014 Dec 16. 42 (22):14013-21

Table-1: Experimental treatment approaches evaluated for efficacy against Ebola virus disease in mammals						
Approach	Target/mechanism of action	Demonstrated Efficacy			Comments	Ref.
		Rodent	NHP	Human		
Vaccines						
Plasmid DNA based vaccine VRC-EBO DNA023-00-VP	DNA immunisation with boosting adenoviral vector	--	Y	Phase I (Uganda)	Process takes 6 months to provide protection in NHP	37
Accelerated vaccine of plasmid DNA based vaccine: ChAd-EBOV, Ad5-EBOV, cAd3-EBOV (GSK) and Ad26 and MVA-EBOV (J&J)	Adenoviral vector delivers DNA encoding Ebola GP	Y	Y	Phase I (UK, U.S, China, Mali, Uganda, Switzerland) Phase II/III: Liberia Phase I: UK, II/III US	Process takes 28 days to provide pre-exposure protection in NHP. Potential for outbreaks. Booster induces longer term protective immunity *NCT02509494	16,46
	MVA used as a second dose booster	--	Y		*NCT02240875, NCT02598388	47
rGP nanoparticle (Novavax)	Recombinant Ebola GP admistered with a saponin based adjuvant (Matrix-M)	--	--	Phase I: Australia	Requires 2 injections	48
rVSV-EBOV (Merck), rVSVΔG-EBOV	VSV delivers Antigen	--	Y	Phase I (Kenya, U.S, Switzerland)	Up to thirty minutes post infection (protection against Ebola -50%, Marburg 100%) 33% protection after 48 hrs, in NHP	7, 11
				STRIVE: Phase II/III Randomized trial in HCWs (Sierra Leone),	Geneva phase I trial halted for safety concerns. Less side effects with the newer strains.	12
				PREVAIL: Phase II (Liberia). Ca Suffit: Phase III (Guinea)	Potentially could provide protection after 6 days of vaccinations in humans. No booster required. Duration of protective antibodies unknown	21
Antibody based therapies						
IgG/IgM from convalescent patients	Virus neutralisation	--	--	Case series, INTERCEPT Phase I and Phase II/III (Guinea, Sierra Leone, Liberia)	Widely used during 2014-15 outbreak. No significant mortality benefit in 99 transfused patients. Two consecutive transfusions of 200-250ml plasma from separate concalescent donors	26,28
Purified IgG	As above	--	Y	Y	48 hrs protection post infection (100%) in NPH	49
Cocktail of 3x mouse monoclonal antibodies-ZMab	Targets GP to neutralize the virus (m1H3, m2G4, m4G7)	--	Y	Cases	100% effective at 24 hrs 50% @ 48 hrs	31
Cocktail combined with adenovirus vectored interferon-alpha	As above	--	Y	--	72 hrs post infection 75-100%	32
Cocktail of 3x humanised monoclonal antibodies (MB-003)	(c13C6, h13F9, c6D8)	--	Y	Cases, Phase I/II trial (multi-centre) Liberia, Sierra Leone, U.S	Protection 100% at 1 hr, 67% at 24/48 hrs. 43% survival at 120 hrs post infection and development of viraemia and fever in NHP.	30,50,
ZMapp and MIL-77 (China)	A combination of chimeric mAB c13C6 from MB-003 and 2 chimeric mABs (c2G4 and c4G7) from ZMab. MIL-77 is produced by CHO cells rather than tobacco plants	-	Y	Phase I	50mg/Kg/day for 3 days *NCT02389192	4, 51 68
Drugs or small molecules						
TKM-Ebola Tekmira	Small interfering RNA cocktail against VP24, VP35, and L protein. Encapsulated in stable nucleic acid lipid particles (SNALP)	--	Y	Phase I-suspended (partial lift by FDA). Phase II: Sierra Leone Cases	IV preparation 100% protection 30 mins post exposure in NHP. Phase II trial halted in Sierra Leone. 7 daily infusions: Day1: 0.3mg/Kg, Day2: 0.4mg/Kg, then Days3-7: 0.5mg/Kg	37
PMOs (AVI-6002)	Blocks mRNA transcription	--	Y	Phase I PEP	62.5% protection within 30 mins in NHP	38
Favipiravir	Pyrazine carboxamide derivative. Selective inhibition of viral RNA dependent RNA polymerase.	Y	--	Cases Phase III (U.S) Licensed in Japan for flu. JIKI Phase II trial in Guinea	Rapid viral clearance, used up to day 6 post infection- mice. Received by most European cases. Preliminary results from JIKI trial indicate effectiveness in cases with low viral load. Day0: 6000mg then Days1-9: 2400mg. Activity being studied in semen NCT02739477	34,35 36
Brincidofovir (CMX001)	Nucleotide analogue. Broad spectrum antiviral.	--	--	Cases Phase II (halted in January 2015)	Developed for CMV, BK viruses. Trial in Liberia halted due to reduction in new cases. Loading dose: 200mg then 100mg twice weekly for total of 5 doses	40,41
BCX4430	Adenosine analogue (PO/IM). Incorporation into viral RNA causing chain termination	--	Y	--	100% protection of NHP at 48 hrs post infection (Marburg virus), also thought to have anti-EVD activity.	32, 39
PO: oral route, IM: Intramuscular route, NHP: Non-human primates, GP: Glycoprotein, VP: Viral protein, VSV: Vesicular stomatitis virus, CHO: Chinese Hamster Ovarian cells mAB: monoclonal antibodies PMOs: Phosphorodiamidate morpholino oligomers, PEP: Post-exposure prophylaxis, FDA: Food and drug agency, MVA: Modified Vaccinia Ankara, GSK:GlaxoSmithKline, J&J: Johnson & Johnson, *Ongoing trials as per http://clinicaltrials.gov (at the time of writing) Note: Military vaccines (Russia, U.S.A and China) were not included in the table given unavailability of publications in scientific journals.						